Cellestial Health develops brain‑penetrant, orally administered small‑molecule drugs that modulate astrocytic networks to protect neuronal function and halt Parkinson’s disease progression. Its multi‑candidate pipeline targets distinct molecular pathways within astrocytes, aiming for disease‑modifying effects that can extend to other neurodegenerative disorders while adhering to sustainable drug‑discovery practices.
Funding
$656.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current Parkinson’s treatments focus on dopamine replacement and only provide temporary symptom relief, leaving the underlying disease progression unchecked. Existing therapies do not address the astrocytic networks that support neuronal function, resulting in limited efficacy for both motor and non‑motor symptoms and significant side‑effect burdens.
Solution
Cellestial Health develops brain‑penetrant small‑molecule drugs that stabilise astrocytic networks, a novel therapeutic target distinct from traditional neuron‑centric approaches. By protecting and normalising astrocyte function, the platform aims to halt disease progression at the time of diagnosis and modify the underlying pathology of Parkinson’s disease. The pipeline comprises multiple candidates, each addressing specific molecular pathways within astrocytic biology, enabling both disease‑modifying effects and broader applicability to other neurodegenerative conditions. Early‑stage candidates are designed for oral administration to ensure accessibility and minimize invasive procedures. The company leverages academic collaborations and a sustainable drug‑discovery process to advance candidates through preclinical and clinical development.
Target Audience
Primary customers are pharmaceutical partners, biotech investors, and clinical research organisations seeking disease‑modifying therapies for Parkinson’s disease and related neurodegenerative disorders.
Features
- Small‑molecule therapeutics engineered for high brain penetration and oral dosing
- Targeted modulation of astrocytic network biology to protect neuronal health
- Multi‑candidate pipeline addressing distinct molecular pathways within astrocytes
- Focus on disease modification rather than symptomatic dopamine replacement
- Development strategy aligned with sustainable pharmaceutical practices and 3R preclinical principles